The emergence of Retatrutide ZPHC, at a strength of 120mg, is creating considerable interest within the medical community. This groundbreaking dual GIP and GLP-1 agonist medication suggests to deliver notable improvements in body reduction compared to previous therapies. Initial patient trials ha